AVITA Medical, Inc.
RCELNasdaqCIK 1762303HealthcareFiscal year ends Dec 31
Reports and events: 156 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1116:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-344787 |
| 2026-08-0616:25 ET | 8-K/A | 5.07 Shareholder vote results | 0001193125-26-338135 |
| 2026-08-0616:20 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-338101 |
| 2026-08-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338011 |
| 2026-06-0819:25 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001762303-26-000011 |
| 2026-06-0419:19 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001762303-26-000003 |
| 2026-05-1416:20 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-224107 |
| 2026-05-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-224022 |
| 2026-05-0116:54 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-201662 |
| 2026-04-2216:30 ET | DEF 14A | Proxy statementPeriod 2026-04-22 | 0001193125-26-170562 |
| 2026-02-1217:20 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-049031 |
| 2026-02-1216:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-048761 |
| 2026-01-1308:30 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-011167 |
| 2026-01-0516:10 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-002418 |
| 2025-11-0616:18 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269597 |
| 2025-11-0616:12 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269535 |
| 2025-10-1719:37 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-241705 |
| 2025-08-1817:16 ET | 8-K | 3.02 Unregistered sale of equity | 0001762303-25-000026 |
| 2025-08-1208:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001762303-25-000023 |
| 2025-08-0819:09 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001762303-25-000014 |
| 2025-08-0716:31 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001762303-25-000012 |
| 2025-08-0616:10 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-104019 |
| 2025-06-0519:26 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-25-081880 |
| 2025-05-1516:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-25-072746 |
| 2025-05-0816:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-066994 |
| 2025-05-0816:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066911 |
| 2025-04-2216:30 ET | DEF 14A | Proxy statementPeriod 2025-04-22 | 0000950170-25-056785 |
| 2025-03-1716:10 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-040249 |
| 2025-02-1317:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-020026 |
| 2025-02-1316:05 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-019862 |
| 2025-01-0716:43 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-002907 |
| 2024-11-0716:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123326 |
| 2024-11-0716:05 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-123279 |
| 2024-08-0816:11 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093964 |
| 2024-08-0816:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093941 |
| 2024-07-3116:11 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-088572 |
| 2024-07-0116:36 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-079679 |
| 2024-06-0616:39 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-24-069945 |
| 2024-05-3016:28 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-066656 |
| 2024-05-1316:04 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-058619 |
| 2024-05-1316:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-058618 |
| 2024-04-2317:09 ET | DEF 14A | Proxy statementPeriod 2024-04-23 | 0000950170-24-047056 |
| 2024-04-1117:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-043776 |
| 2024-02-2216:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-018748 |
| 2024-02-2216:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-018735 |
| 2024-01-1016:05 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-003621 |
| 2023-11-0916:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062036 |
| 2023-11-0916:07 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062024 |
| 2023-10-2316:36 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-054644 |
| 2023-10-1809:07 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000950170-23-053882 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.